Abstract: Post-transplant malignancies present an aggressive course and are a significant cause of morbidity and mortality. Tumours of viral ethiology have the greatest risk in renal transplant recipients. Oncogenic effect of immunosuppressive therapy is another major risk factor of post-transplant malignancy. We report cases of three different types of malignancies developed after kidney transplantation: non-Hodgkin's lymphoma, Kaposi's sarcoma and germ cell testicular cancer (nonseminoma).
Introduction
Transplant patients have a higher incidence of malignancies, and the types of them are different to compare with general population [1] [2] [3] . The relative risk of malignancies ranges from 2-3 fold increase for common malignancies (lung, prostate, breast, colon) to a 100-fold increase for nonmelanomatous skin cancers, lymphomas and Kaposi's sarcoma [1] [2] [3] [4] [5] [6] [7] . Comparison with hemodialysis patients shows 10-times higher risk of malignancy in transplantated patients [8, 9] . The cumulative prevalence of malignancy increases with the duration of follow-up [10] .
Case 1
A 41-year-old man, with a 3-year history of hemodialysis, received a cadaveric renal transplant in January 2010.
The cause of end -stage renal disease was bilateral hypoplastic kidneys. The post-transplant period was uneventful and graft function was excellent. Immunosuppression consisted of cyclosporine (150 mg; the serum cyclosporine level was in the range of 90-115µg/l), azathioprine (50 mg) and methylprednisolone (8 mg) . Ten months after transplantation, the patient was presented to outpatient department complaining of general weakness, loss of appetite and decrease of weight. On physical examination, his weight was 50 kg, and BMI 17,3 kg/ m 2 . Laboratory investigation showed good graft function (serum creatinine 78 µmol/l) and slight hypoproteinemia (total protein 55 g/l, serum albumin 33 g/l). Gastroscopy revealed only few erosions in antral part. Chest x-ray showed no pulmonary opacities. Abdominal ultrasound revealed hypoechogeneous multiple lesions in the right lobe of the liver, suggestive metastatic lesions.
The patient was admitted to nephrology department for further assessment. Computerized tomography (CT) of the abdomen confirmed the presence of multifocal nodules (0,2-2,1 cm) in the liver and spleen and 1,4x1,5 cm hypodense node in transplanted kidney, typical to metastatic changes. The liver biopsy was performed. Histological evaluation revealed several polymorphic infiltrates, consisting mainly of medium-sized lymphoid cells positive for CD20, BCL-2, negative for CD3 (positive for small T lymphocytes), BCL-6, CD10, Cyclin D1 (Figure 1, A, B and C) . The diagnosis of diffuse large B-cell lymphoma was confirmed. After that, immunosuppression was reduced: azathioprine was stopped, dose of cyclosporine was reduced by half (75 mg). Methylprednisolone dose (8 mg) was left unchanged. The treatment of lymphoma consisted of 8 cycles of R-CHOP chemotherapy in standart dosage (rituximab + doxorubicin + cyclophosphamide + vincristine + methylprednisolone). After chemotherapy, the metastatic nodular lesions in the liver, spleen and transplant kidney disappeared. Graft function remained normal. With the aim to minimize the risk of malignancy recurrence, immunosuppression scheme was changed: cyclosporine was switched to sirolimus and mycofenolate mofetil was appointed instead of azathioprine. The patient is under the follow-up by nephrologist and oncologist. One year after lymphoma treatment, no malignancy recurrence was observed.
Case 2
A 57-year-old man,with end-stage renal disease secondary to hypertensive nephropathy, was on maintain haemodialysis for 5 years. At the end of 2009, he received a cadaveric renal transplant. Immunosuppressive therapy included cyclosporine (250 mg; serum cyclosporine level was in the range of 98-120 µg/l), mycofenolate mofetil (2g) and methylprednisolone (6 mg). The graft function was satisfactory (serum creatinine 200 µmol/l). Fourteen months after transplantation, a skin rash had occurred in the legs (Figure 2 , A, B and C). The patient was referred to dermatologist and skin biopsy was performed. Very soon after that, hydronephrosis and pyelonephritis developed in transplanted kidney. Graft function deteriorated significantly (serum creatinine 721 µmol/l), requiring few sessions of haemodialysis. The patient was referred to urologist and nephrostoma was performed, graft function improved. At that time, results of skin biopsy were obtained ( Figure 3 , A and B). Histology revealed Kaposi's sarcoma. The sonography of the abdomen showed conglomerates of enlarged inguinal lymph nodes. Immunosuppression was reduced: mycofenolate mofetil was stopped, dose of cyclosporine was reduced by half (125 mg), methylprednisolone continued unchanged (6 mg). Treatment of Kaposi's sarcoma was started with doxorubicin 15mg/ m². Few days later, pyelonephritis developed again in transplanted kidney with severe graft dysfunction (serum creatinine 1135 µmol/l). Haemodialysis was restarted. Treatment with antibiotics was ineffective, septic complications progressed. CT scan revealed abscess in transplanted kidney, extension of infiltration to surrounding graft tissue, and pelvic blood vessels. CT scan showed also multiple enlarged lymph nodes in the Bleomycin was omitted at first cycle day 1 and day 15 (latter due to febrile neutropenia, trombocytopenia, anemia); at cycle 2-day 1 and day 15 (latter due to trombocytopenia); at cycle 3-day 15 (due to trombocytopenia); at cycle 4-day 15 (due to febrile neutropenia, trombocytopenia and anemia).
Renal function remained stable with creatinine ranges in 169-104-150 mcmol/l during all treatment period. Immunosuppression with cyclosporine (225 mg) and methylprednisolone (4 mg) was continued, azathioprine Follow up visits were every 2-3 months. Until 02/2012-no signs of tumor progression: tumor markers were in normal ranges; chest, abdominal and pelvic CT showed no metastasis or pathological lymph nodes. Patient's performance status was good. Renal graft function was in adequate values.
Discussion
Malignancy is the third major cause of death in kidney transplant recipients (first two are cardiovascular diseases and infections) [9, 11, 12] . The main risk factors of post-transplant malignancy are immunosuppression and oncogenic virus. They both induced tumors after kidney transplantation. Immunosuppresion can accelerate the occurrence of cancer. [7, [13] [14] [15] . We reported 2 cases of post-transplant malignancy, associated with viral infections. First case is B-cell lymphoma (non-Hodgkin's). This lymphoproliferative disease is related to Epstein-Barr virus (EBV) [16] . Seronegative recipients which receive an organ from a seropositive donor are at highest risk. Anti-lymphocyte antibodes (ATG, OKT3) or large doses of cyclosporine or tacrolimus and azathioprine also increase the risk [17] [18] [19] [20] . EBV transforms B-lympocytes and promote uncontrolled proliferation [16, 20, 21] . In our case, lymphoma developed within first year after kidney transplantation and presented with lymphadenopathy and extranodal involvement of liver, spleen, graft. It presented a typical course of disease. Significant reduction of immunosuppression and treatment with rituximab and conventional chemotherapy (CHOP) reversed the process. Graft function remained in normal value. To reduce malignancy reccurency, cyclosporine was changed to sirolimus and azathioprine to mofetil mycofenolate. Some clinical evidence suggests that the incidence of post-transplantation malignancy is lower in patients receiving sirolimus or everolimus than in patients receiving other immunosupressive therapies [5, 22, 23] . Mammalian Target of Rapamycin (mTOR) inhibitors presents antineoplastic effects by direct inhibition of cancer cell replication, by induction of apoptosis and inhibition of IL-10, vascular endothelial growth factor (VEGF) production and inhibition of angiogenesis [24, 25] . MMF also may have a protective effect against malignancy. Some studies indicated an antitumor effect against colon and prostate cancer cells, others found MMF to be associated with a decrease in the relative risk of developing post-transplant lymphoproliferative disorder (PTLD) compared to AZA [24] . Antiviral agents were not given to our patient with lymphoma as they are not recommended. Few studies have examined outcomes after lymphoma diagnosis. They found that posttransplant lymphoma is associated with a 17-fold increased risk of death due to disease complications [26] .
The second case is Kaposi's sarcoma, related to Human Herpesvirus-8 (HSV-8). It presented 14 months later after kidney transplantation with macular skin lesion and later disseminated to lymphnodes. According to the literature, in 40 percent of cases the clinical course is aggressive with involvement of visceral organs, and may respond to reduction of the doses of immunosuppressive agents what leads to complete remission in 30 percent of the patients [27] . Others recommend to switch to sirolimus, but sometimes chemotherapy or radiotherapy are required [6] . The use of sirolimus in place of ciclosporin has been associated with complete regression of Kaposi's sarcoma in renal transplant recipients [28, 29] . In our case we stopped immunosuppression and removed the graft because of infection complication (abscess) in transplanted kidney. Haemodialysis was started and treatment with doxorubicin was given after what skin rash disappeared and lymphnodes decreased. The second line monochemotherapy is etoposide, vinblastine, doxorubicin, bleomycin and vincristine or combinations of these drugs [30, 31] .
The third our report is about very rare case of posttransplant malignancy. There are little literature data on metastatic testicular germ cell cancer after renal transplantation. Germ cell testicular tumors account for only 1.7 % of all de novo cancers after renal transplantation [32] . According to clinical experience in medical literature it is recommended to choose standard chemotherapy with cisplatin [32] or carboplatin [33] , etoposide, bleomycin [32] . Dose reduction could be up to 25-50% and close monitoring of renal function is mandatory. Also prophylactic GCSF for febrile neutropenia prevention is recommended. It is also recommended before chemotherapy discontinue azathioprine while leaving cyclosporine and glucocorticoids for immunosuppression [32] . Some authors suggest switching cyclosporine to sirolimus, which presents antiproliferative, antineoplastic effect [5, 7] . Our patient developed germ cell testicular malignancy with multiply metastasis 3 years after kidney transplantation. We started with chemotherapy with reduced doses of carboplatin and etoposide only by 25% while keeping full doses of bleomycin. We realized full complex treatment with GCSF prophylactic which led to tumor regression following tumor masses resection from transplanted kidney, left lung and retroperitoneal lymph nodes. Graft function remained in adequate values. Immunosuppression was continued with sirolimus (instead of cyclosporine), mycofenolate mofetil and methylprednisolone.
Early diagnose and treatment of posttransplant malignancies is very important. Preventive strategies and detecting of malignancies in the transplant patients relies upon periodic examinations and strict adherence to prophylactic measures. Specific problems relating to screening of malignancies after kidney transplantation are discussed in the American Society of Transplantation (AST) Clinical Practice Guidelines and European Best Practice Guidelines [34, 35] . Guidelines recommends for liver cancer screening to monitor liver function tests with routine lab work, ultrasound of abdomen every 6-12 months, in presence of hepatitis C or B to check alpha-fetoprotein every 6-12 months, for cervical cancer screening -annual Pap smear and pelvic exam, especially in HPV+, for breast cancer-yearly mammogram for women over 40 years old, for prostate carcinoma-yearly rectal exam and PSA [34, 35] .
In preventive of malignancies is important not only careful screening of the kidney recipients but the donors also. It helped to prevent underlying preexisting malignancies in donors. Today we have available abundant information in regard to transmission risk of donor-recipient tumor thanks to registries such as Israel Penn Transplant Tumor Registry [36] , United Network for Organ Sharing Registry [37] , The Spanish National Transplant Organization (ONT) Tumor Registry [38] and others. Transmission of a tumor from donor to the recipients is rare [36, 38] , but we cannot forget that the risk exists. Malignant melanoma, choriocarcinoma, lymphoma, carcinoma of the lung, breast, colon, renal cell cancer belong to malignancies with an increased risk of donor to recipient transmission [36] .
Conclusions
This report highlights the importance of cancer screening after renal transplantation. The screening shoud not be limited only to common malignancies as limphoproliferative disease, Kaposi sarcoma, skin cancer. One from our three reported cases was very rare embrional testicular carcinoma. Early diagnosis and treatment of posttransplant malignancies were successful in our patients. Preventive strategies as control of oncogenic virus must be implemented after transplantation in an attempt to reduce the development of malignant tumors.
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